An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX, in subjects >= 70 years of age
Phase 3
Completed
- Conditions
- Herpes ZosterShingles10047438
- Registration Number
- NL-OMON31421
- Lead Sponsor
- Sanofi Pasteur MSD S.N.C.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
70 years or older, varicella history-positive or residence for > 30 years in a country with endemic VZV infection
Exclusion Criteria
Febrile within the last 72 hours before vaccination, history of hypersensitivity/anaphylactoid reaction to ZOSTAVAX components including gelatine or neomycin, prior herpes-zoster episode clinically diagnosed by a physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method